HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Set To Maintain Safe Intake Levels For Vitamin D And Folate In Supplements

Executive Summary

Positive news for dietary supplement manufacturers as EFSA plans to maintain the existing tolerable upper intake levels for vitamin D and folate. The regulator recently revealed plans to cut levels for vitamin B6 and selenium.

You may also be interested in...

EU’s Proposed Safe Limit For Vitamin B6 In Supplements 8 Times Lower Than US Cap

EFSA has halved its tolerable upper intake level for vitamin B6 in supplements to 12mg/day, a limit more than eight times lower than the cap set by the US and the World Health Organization. Hylobates Consulting's Luca Bucchini expects that this lower UL will push the EU to set a maximum permitted level for vitamin B6 in supplements which is "massively lower" than currently applied by some member states.

EFSA's Lower Safe Intake Level For Selenium Stands Despite Supplement Industry’s Objections

The European Food Safety Authority has rejected a request from industry association Food Supplements Europe to apply its new lower intake limit for selenium to only selenomethionine and not other forms authorized for use in supplements.

Nestlé Partner Valbiotis Hails Trial Results For Prediabetes Supplement

Valbiotis and Nestlé Health Science plan to launch in 2024 a dietary supplement targeted at sufferers of prediabetes and type-2 diabetes following positive results from a recent study which showed the product's efficacy on key markers of glucose metabolism.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts